Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541768 | 1.00 | GPR119 (0.51) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL2541769 | 1.00 | GPR119 (0.51) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL2545449 | 1.00 | GPR119 (0.51) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL1550695 | 1.00 | GPR119 (0.51) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL2545446 | 1.00 | GPR119 (0.51) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL1550790 | 0.88 | GPR119 (0.44) | GPR119KCNH2SCDCHRM4 | |
| SCHEMBL2335683 | 0.87 | GPR119 (0.63) | GPR119KCNH2SCDKDM1ATRPV4 | |
| SCHEMBL14237609 | 0.81 | GPR119 (0.40) | GPR119KDM1ATRPV4 | |
| SCHEMBL12391230 | 0.81 | GPR119 (0.65) | GPR119KCNH2SCDKDM1A | |
| SCHEMBL2333652 | 0.81 | GPR119 (0.65) | GPR119KCNH2SCDKDM1ATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313395-B1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-19 | — | — | EP | claimed |
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-23 | — | — | US | disclosed |
| US-8372837-B2 | Pyridone and pyridazone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131074-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885KCNH2 929/4885SCD 4268/4885 |
| US-20110263548-A1 | PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR4, GPR3 | GPR119 1/4885KCNH2 869/4885SCD 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.